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Abstract
Background: The incidence of non-tuberculous mycobacteria (NTM) isolation from humans is increasing worldwide. In
England, Wales and Northern Ireland (EW&NI) the reported rate of NTM more than doubled between 1996 and 2006.
Although NTM infection has traditionally been associated with immunosuppressed individuals or those with severe
underlying lung damage, pulmonary NTM infection and disease may occur in people with no overt immune deficiency.
Here we report the incidence of NTM isolation in EW&NI between 2007 and 2012 from both pulmonary and
extra-pulmonary samples obtained at a population level.
Methods: All individuals with culture positive NTM isolates between 2007 and 2012 reported to Public Health England
by the five mycobacterial reference laboratories serving EW&NI were included.
Results: Between 2007 and 2012, 21,118 individuals had NTM culture positive isolates. Over the study period the
incidence rose from 5.6/100,000 in 2007 to 7.6/100,000 in 2012 (p < 0.001). Of those with a known specimen type,
90 % were pulmonary, in whom incidence increased from 4.0/100,000 to 6.1/100,000 (p < 0.001). In extra-pulmonary
specimens this fell from 0.6/100,000 to 0.4/100,000 (p < 0.001).
The most frequently cultured organisms from individuals with pulmonary isolates were within the M. avium-intracellulare
complex family (MAC). The incidence of pulmonary MAC increased from 1.3/100,000 to 2.2/100,000 (p < 0.001). The
majority of these individuals were over 60 years old.
Conclusion: Using a population-based approach, we find that the incidence of NTM has continued to rise since the last
national analysis. Overall, this represents an almost ten-fold increase since 1995. Pulmonary MAC in older individuals is
responsible for the majority of this change.
We are limited to reporting NTM isolates and not clinical disease caused by these organisms. To determine whether the
burden of NTM disease is genuinely increasing, a standardised approach to the collection of linked national
microbiological and clinical data is required.
Keywords: Nontuberculous mycobacteria, Mycobacterium avium-intracellulare complex, Incidence, Environmental
mycobacterium
* Correspondence: marclipman@nhs.net
Marc Lipman and Ibrahim Abubakar are joint last authors
†Equal contributors
4UCL Respiratory, Division of Medicine, University College London, London,
UK
Full list of author information is available at the end of the article
© 2016 Shah et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shah et al. BMC Infectious Diseases  (2016) 16:195 
DOI 10.1186/s12879-016-1521-3
Background
The frequency of isolation of nontuberculous mycobac-
teria (NTM) from human clinical samples is increasing
worldwide [1]. In England, Wales and Northern Ireland
(EW&NI), the incidence of NTM in all sample types was
previously reported to have almost trebled between 1995
(0.9 per 100,000 population) and 2006 (2.9 per 100,000
population) [2].
Unlike Mycobacterium tuberculosis, which is a genuine
pathogen, the largely environmental NTM have been
often associated with conditions of host impaired
immunity, such as primary immunodeficiency, HIV or
the use of immunosuppressive medication [3]. Increas-
ingly, NTM are isolated in immunocompetent individuals,
with or without pre-existing structural lung damage [4]. It
is not clear why this is so, and possible explanations
include an increase in the number of individuals with
structural lung damage making them more susceptible to
mycobacterial infection, more mycobacteria in the
environment, improved laboratory detection techniques,
a greater awareness of their potential relevance - resulting
in more frequent mycobacterial culture being performed,
or the result of more investigation to exclude M.
tuberculosis.
Here, using population-based data, we report the
incidence of NTM isolation in EW&NI between 2007
and 2012. We demonstrate that whilst there has been a
significant increase in a number of NTM, the overall rise
is largely explained by pulmonary Mycobacterium
avium-intracellulare complex.
Methods
All culture positive NTM isolates between 2007 and
2012 reported to Public Health England (PHE) by the
five mycobacterial reference laboratories serving EW&NI
were included. Age and sex were routinely collected,
along with the site of the specimen and NTM species
identified from the culture. Between 2007 and 2012, M.
avium, M. intracellulare and other related organisms,
(eg M. chimaera), were grouped as M. avium-
intracellulare complex (MAC). The rapid growers within
M. abscessus family (eg M. abscessus ssp. abscessus, M.
abscessus ssp. bolletii, and M. abscessus ssp. massiliense)
were identifed as M. abscessus.
Isolates were probabilistically de-duplicated using pa-
tient identifiers to report each individual once [5], based
on their earliest specimen date between 2007 and 2012.
If an individual had multiple NTM organisms isolated,
the organism with the earliest specimen date was
included. The site of infection was inferred from the
specimen site.
The annual incidence of NTM was calculated using
the de-duplicated individual level NTM data and mid-
year population estimates from the Office of National
Statistics. A chi-squared test for trend was used to
analyse the change in incidence between 2007 and 2012.
Confidence intervals for incidence were calculated as-
suming a Poisson distribution for the number of events.
All analyses were conducted using Stata 13.1, Stata
Corporation, Texas, USA. Incidence rates are expressed
per 100,000 population. Means are reported with standard
deviation.
Results
Between 2007 and 2012, 21,118 individuals had NTM cul-
ture positive isolates in EW&NI. The overall incidence of
NTM increased from 5.6/100,000 (n = 3,126, 95 % CI 5.4–
5.7) to 7.6/100,000 (n = 4,454, 95 % CI 7.4–7.9) (p < 0.001;
Fig. 1). 16.2 % of individuals had cultures positive for M.
gordonae. As this is considered non-pathogenic in much
of the literature, the rates were recalculated without these
isolates. Again the incidence rose (from 4.8/100,000
(n = 2,718, 95 % CI 4.6–4.9) to 6.3/100,000 (n = 3,651,
95 % CI 6.2–6.5), p < 0.001). During the study period
46 different mycobacterial species were identified. More
than one NTM species was isolated in 2,100 (10 %)
individuals. Species could not be identified in 2.4 %.
Of those with a known specimen site (85.0 %, n =
17,932), 90.9 % (n = 16,294) had a pulmonary isolate.
Fifty-eight percent of these were in men; and the mean
(± standard deviation) age of the pulmonary population
was 60 ± 20 years. This compares to 53 ± 25 years in
those with extra-pulmonary isolates. Ages are expressed
as age ± standard deviation.
In people with pulmonary isolates, the incidence rose
from 4.0/100,000 (n = 2,241, 95 % CI 3.8–4.1) to 6.1/
100,000 (n = 3,551, 95 % CI 5.9–6.3, p < 0.001). In
contrast, over the same period it fell in individuals with
extra-pulmonary isolates (0.6/100,000, 95 % CI 0.58–
0.63 to 0.4/100,000, 95 % CI 0.39–0.41, p < 0.001).
16.6 % of individuals with pulmonary isolates had cul-
tures positive for M. gordonae. As above, incidence rates
were recalculated without these isolates. Incidence rose
from 3.4/100,000 (n = 1,893, 95 % CI 3.3–3.5) to 5.0/
100,000 (n = 2,905, 95 % CI 4.9–5.1, p < 0.001).
Organisms in pulmonary samples
The most frequent NTM cultured from pulmonary sam-
ples was M. avium-intracellulare complex (MAC; 35.6 %,
n = 5,800). Other organisms commonly isolated were M.
gordonae (16.7 %), M. chelonae (9.6 %), M. fortuitum
(8.2 %), M. kansasii (5.9 %), M. xenopi (5.9 %), and M.
abscessus (5.0 %) (Table 1 and Fig. 2).
The incidence of individuals with pulmonary MAC
isolates increased from 1.3 (95 % CI 1.2–1.4) in 2007 to
2.2 (95 % CI 2.1–2.4) in 2012 (p < 0.001). This increase
was observed in both males and females (Fig. 3). The
majority of pulmonary MAC was isolated from older
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individuals – with around two-thirds of men and women
being aged over 60 (Fig. 4). There was also a significant
increase in incidence of M. chelonae, M. fortuitum and
M. gordonae (p < 0.001); whilst that of M. kansasii fell
(p < 0.001).
M. abscessus had a bi-phasic age distribution with
peaks within the age groups 10–19 and 70–79 years.
This was unlike other rapid growers such as M. fortui-
tum and M. chelonae, where the incidence rose steadily
with age (Fig. 5).
Organisms in extra-pulmonary samples
The most frequent organisms cultured from extra-
pulmonary samples were MAC (34 %), M. chelonae
(15.8 %) and M. gordonae (14.3 %) (Table 1). Between
2007 and 2012, there was no significant change in
incidence in extra-pulmonary MAC isolates (Fig. 3). Un-
like other specimen sites, individuals with cultures from
lymph nodes were younger, with a mean age of 21 ±
25 years. In these individuals, the most frequent organ-
isms were MAC (62.7 %), M. malmoense (14.8 %) and
M. chelonae (10.9 %). M. marinum accounted for 28.7 %
of cutaneous isolates.
Discussion
This population-based study demonstrates that the
NTM incidence in submitted samples from EW&NI has
continued to rise since the last national investigation [2].
Fig. 1 Incidence of isolation of NTM in England, Wales and Northern Ireland 2007–2012
Table 1 The relationship between NTM and their isolation from different specimen sites
Organism Total Pulmonary Blood Lymph node Urine Other Unknown
n n % n % n % n % n % n %
M. avium-intracellulare 7436 5800 35.6 120 30.7 161 62.6 65 18.4 187 29.4 1103 34.6
M. gordonae 3414 2721 16.7 2 0.5 2 0.8 99 28.0 33 5.2 557 17.5
M. chelonae 2342 1574 9.7 130 33.2 28 10.9 53 15.0 153 24.1 404 12.7
M. fortuitum 1698 1330 8.2 33 8.4 5 1.9 38 10.7 52 8.2 240 7.5
M. kansasii 1131 966 6.0 2 0.5 4 1.6 12 3.4 32 5.0 115 3.6
M. xenopi 1069 958 5.9 1 0.3 2 0.8 8 2.3 10 1.6 90 2.8
M. abscessus 992 812 5.0 14 3.6 7 2.7 1 0.3 24 3.8 134 4.2
M. malmoense 931 718 4.4 2 0.5 38 14.8 5 1.4 29 4.6 139 4.4
M. peregrinum 489 414 2.5 11 2.8 2 0.8 16 4.5 9 1.4 37 1.2
M. mucogenicum 258 161 1.0 58 14.8 1 0.4 7 2.0 11 1.7 20 0.6
M. marinum 166 1 0.01 0 0 0 0 0 0 75 11.8 90 2.8
Other 1192 839 5.1 18 4.6 7 2.7 50 14.1 21 3.3 257 8.1
“Other” in specimen site category includes specimens from bone, cerebrospinal fluid, eyes, faeces, gastrointestinal tract, peritoneal dialysis fluid, peritoneal fluid,
skin and synovial fluid
“%” refers to percentage of NTM species contributing to total for given body site
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Much of this appears to be due to an increase in NTM
in pulmonary isolates, most frequently obtained from
older individuals. MAC was the commonest group of
cultured organisms from both pulmonary and extra-
pulmonary sites. It is noteworthy that the incidence of
extra-pulmonary isolates decreased over the same time
period over the same time period.
The observed rise in the incidence of NTM in EW&NI
is in line with reports from other countries [6, 7], though
not Scotland, where there has been no change between
2000 and 2010 [8]. Our finding of pulmonary MAC being
the largest contributor to NTM incidence is consistent
with a population-based study from Oregon, USA [6].
M. abscessus demonstrated a spike in incidence in
both younger and older patients, with the majority of iso-
lates found in individuals less than 30 years. Due to the
lack of clinical data, we cannot relate this directly to cystic
fibrosis (CF), though it is likely that this contributes to the
isolates obtained from the younger population where it is
an important clinical problem [9]. This is consistent with
a recent report from Scotland [8].
M. chelonae and M. mucogenicum were associated
with bloodstream infections. 70 % of cutaneous isolates
were M. marinum or rapidly growing NTM, which has
also been noted by others [10].
There are several possible explanations for the increase
in NTM isolation. These include recent environmental
changes leading to more NTM in soil or water [3]. In
support of this, Khan et al. [11] demonstrated a signifi-
cant increase in skin sensitization to M. intracellulare in
the general population in the United States between
1971 and 1972 and 1999–2000. A true rise in the
amount of NTM in the environment should also be
reflected by a similar increase in extra-pulmonary
Fig. 2 Most frequently isolated NTM organisms in pulmonary samples, 2007–2012
Fig. 3 The incidence of M. avium-intracellulare isolation, 2007–2012
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cultures. However this has actually declined, suggesting
that environmental factors are not the only explanation.
More individuals may now be susceptible to pulmonary
NTM colonisation and disease. Older males, who were
most likely to have a positive NTM culture, are a
population with more chronic respiratory disease re-
quiring prescribed drug therapies (including inhaled
corticosteroids) that increase the risk of NTM lung
disease [12]. Furthermore, the number of people using
immunosuppressive and biological agents is rising.
Brode et al. [13] reported that anti-TNF therapy dou-
bled the risk of NTM disease (OR 2.19, 95 % CI
1.10–4.37). Also, a patient’s underlying clinical illness
may be relevant. For example, rheumatoid arthritis
has itself been associated with NTM disease [14, 15].
Clearly these explanations are not mutually exclu-
sive; and over time could lead to a yet further in-
crease in incidence as clinicians become more aware
of NTM disease and so perform more mycobacterial
diagnostic tests.
A strength of our study is that we are confident we are
counting only single isolates from individuals, and hence
avoiding duplication (and inflation) of our results. The
natural history of NTM (where an individual will isolate
often multiple samples over an extended period of time)
means that this is a common problem when dealing with
this condition [2]. We believe that the absolute number
of NTM isolates being reported to Public Health
England has genuinely increased. However as only the
earliest culture result was included in our study in those
individuals who had positive cultures of more than one
NTM organism (10 %), there is a risk we may have
introduced bias towards rapid growers at the expense of
slower growers. Despite this, the predominant NTM was
MAC, a slow-growing group of organisms.
To determine whether the burden of NTM disease is
also increasing requires an understanding of current
clinical and laboratory practice. In EW&NI there is no
standardised approach to the investigation of suspected
NTM patients, and the systematic collection of relevant
Fig. 4 The incidence of M. avium-intracellulare in pulmonary samples, by age-group, across all years of this study
Fig. 5 Incidence of rapidly-growing NTM in pulmonary samples, grouped by age across all years 2007–2012
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clinical data related to NTM isolates is limited. This
needs to change if we are to better understand NTM
disease and improve on current management strategies
and outcomes.
Conclusion
The continuing rise in the isolation of NTM between
2007 and 2012, driven primarily by pulmonary MAC in
older individuals warrants further investigation. It is now
imperative that standardised clinical data are collected
on all individuals with positive NTM isolates across the
country to determine if there is a genuine increase in
NTM disease. This will allow determination of clinical
risk groups and reasons for this increase, and justify
targeting the development of the management of
pulmonary MAC.
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